Compare · GYRE vs NVO
GYRE vs NVO
Side-by-side comparison of Gyre Therapeutics Inc. (GYRE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GYRE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 289.3x GYRE ($744.9M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 8 for GYRE).
- NVO has more recent analyst coverage (25 ratings vs 3 for GYRE).
- Company
- Gyre Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $744.9M
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2006
- News (4w)
- 8
- 9
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest GYRE
- SEC Form 10-Q filed by Gyre Therapeutics Inc.
- Gyre Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Gyre Therapeutics Reports Second Quarter 2026 and Year-to-Date Financial Results and Provides Business Update
- SEC Form 4 filed by Director Weston Claire
- SEC Form 4 filed by Director Kirkby Maxwell
- SEC Form 3 filed by new insider Weston Claire
- SEC Form 3 filed by new insider Kirkby Maxwell
- SEC Form EFFECT filed by Gyre Therapeutics Inc.
- Gyre Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure
- Gyre Therapeutics Appoints Three New Members to its Board of Directors
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S